Trial Profile
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Alvocidib (Primary) ; Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms Zella 102
- Sponsors Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America; Tolero Pharmaceuticals
- 20 Oct 2022 Status changed to discontinued.
- 21 Oct 2021 Status changed from active, no longer recruiting to completed.
- 29 Apr 2021 Planned primary completion date changed from 1 Feb 2023 to 1 Sep 2021.